Cutaneous head and beck squamous cell carcinoma metastatic to parotid and cervical lymph nodes

Veness, M., Porceddu, S.V., Palme, C. and Morgan, G. (2007) Cutaneous head and beck squamous cell carcinoma metastatic to parotid and cervical lymph nodes. Head & Neck, 29 7: 621-630. doi:10.1002/hed.20576

Author Veness, M.
Porceddu, S.V.
Palme, C.
Morgan, G.
Title Cutaneous head and beck squamous cell carcinoma metastatic to parotid and cervical lymph nodes
Journal name Head & Neck   Check publisher's open access policy
ISSN 1043-3074
Publication date 2007-07-01
Year available 2007
Sub-type Article (original research)
DOI 10.1002/hed.20576
Open Access Status Not yet assessed
Volume 29
Issue 7
Start page 621
End page 630
Total pages 10
Place of publication USA
Publisher Wiley Interscience
Language eng
Subject CX
920102 Cancer and Related Disorders
111202 Cancer Diagnosis
Abstract Nonmelanoma skin cancers occur at an epidemic rate in Australia and are increasing in incidence worldwide. In most patients, local treatment is curative. However, a subset of patients will be diagnosed with a high-risk cutaneous squamous cell carcinoma (SCC) and are defined as patients at increased risk of developing metastases to regional lymph nodes. Patients with high-risk SCC may be identified based on primary lesion and patient factors. Most cutaneous SCC arises on the sun-exposed head and neck. The parotid and upper cervical nodes are common sites for the development of metastases arising from ear, anterior scalp, temple/forehead, or scalp SCC. The mortality and morbidity associated with high-risk cutaneous SCC is usually a consequence of uncontrolled metastatic nodal disease and, to a lesser extent, distant metastases. Patients with operable nodal disease have traditionally been recommended for surgery. The efficacy of adjuvant radiotherapy has previously been questioned based on weak evidence in the early literature. Recent evidence from larger studies has, however, strengthened the case for adjuvant radiotherapy as a means to improve locoregional control and survival. Despite this, many patients still experience relapse and die. Research aimed at improving outcome such as a randomized trial incorporating the addition of chemotherapy to adjuvant radiotherapy is currently in progress in Australia and New Zealand. Ongoing research also includes the development of a proposed new staging system and investigating the role of molecular factors such as the epidermal growth factor receptor. (c) 2007 Wiley Periodicals, Inc.
Keyword Otorhinolaryngology
Q-Index Code CX
Institutional Status Non-UQ

Document type: Journal Article
Sub-type: Article (original research)
Collections: Excellence in Research Australia (ERA) - Collection
School of Medicine Publications
Version Filter Type
Citation counts: TR Web of Science Citation Count  Cited 98 times in Thomson Reuters Web of Science Article | Citations
Scopus Citation Count Cited 105 times in Scopus Article | Citations
Google Scholar Search Google Scholar
Created: Wed, 26 Aug 2009, 20:32:25 EST by Denise Wilson on behalf of Medicine - Princess Alexandra Hospital